| Literature DB >> 35682408 |
Agnieszka Trawicka1,2, Aleksandra Lewandowska-Walter3, Mikołaj Majkowicz4, Robert Sabiniewicz1, Lidia Woźniak-Mielczarek1.
Abstract
BACKGROUND: Despite extensive knowledge about the quality of life of people suffering from rare diseases, data on patients with Marfan syndrome (MFS) are scarce and inconsistent. Hence, the problem of assessing the quality of life (QOL) and its relationship with the assessment of which ailments are the most burdensome for these patients is still open. AIM: Comparison of the quality of life of patients with MFS and determination as to which of the reported complaints in patients with MFS are related to the QOL of patients.Entities:
Keywords: Marfan syndrome; aortic aneurysm; health-related quality of life; quality of life; rare genetic diseases
Mesh:
Year: 2022 PMID: 35682408 PMCID: PMC9180829 DOI: 10.3390/ijerph19116827
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Demographic data concerning both studied groups.
| Variable | People with Marfan Syndrome (N = 35) | Healthy People (N = 33) | ||
|---|---|---|---|---|
| M | SD | M | SD | |
| Age | 32.68 | 11.97 | 33.03 | 11.95 |
| N | % | N | % | |
| Sex: | ||||
| Women | 21 | 60 | 21 | 63.64 |
| Men | 14 | 40 | 12 | 36.36 |
| Professional activity: | ||||
| Professionally active | 11 | 31.43 | 5 | 15.15 |
| Professionally inactive | 23 | 65.71 | 26 | 78.79 |
| Education: | ||||
| Basic or vocational | 3 | 5.57 | 1 | 3.03 |
| Secondary | 16 | 45.71 | 11 | 33.33 |
| Higher | 15 | 42.86 | 20 | 60.61 |
| Residence: | ||||
| Village | 10 | 28.57 | 2 | 6.06 |
| Town > 30,000 inhabitants | 6 | 17.14 | 5 | 15.15 |
| City 30,000–100,000 inhabitants | 8 | 22.86 | 7 | 21.21 |
| City over 100,000 inhabitants | 10 | 28.57 | 17 | 51.51 |
| Relationship: | ||||
| People in a steady relationship | 20 | 57.14 | 21 | 63.64 |
| People not in a relationship | 14 | 40 | 9 | 27.27 |
| Financial situation | ||||
| Above the average | 9 | 25.71 | 21 | 63.63 |
| Average | 19 | 54.26 | 10 | 30.30 |
| Rather bad or bad | 5 | 2.86 | 1 | 3.03 |
| Membership of Marfan Poland Association | ||||
| Yes | 18 | 60 | ||
| No | 12 | 40 | ||
Clinical data concerning people with Marfan syndrome.
| Variable | Number |
|---|---|
| Marfan syndrome: | |
| de novo | 7 |
| familial | 15 |
| Aorta condition: | |
| Dissected aorta | 19 |
| Non-dissected aorta | 8 |
| Result from the upper part of the norm | 2 |
| Dissection or rupture of aneurysm | 3 |
| The course of the disease: | |
| With a cardiac surgery | 7 |
| Without a cardiac surgery | 21 |
Medical data concerning Ghent criteria in people with Marfan syndrome.
| Ghent Criteria | M |
|---|---|
| Total number of points in Ghent scale | 7.63 |
| n | |
| Thumb or wrist symptoms: | |
| Thumb symptom | 22 |
| Wrist symptom | 19 |
| Symptoms connected with chest: | |
| Pigeon chest | 16 |
| Pectus excavatum | 8 |
| Chest asymmetry | 22 |
| Symptoms connected with feet: | |
| Metatarsal deformation | 7 |
| Flat foot | 14 |
| Both criteria fulfilled | 5 |
| Pneumothroax | 1 |
| Reduced relation of the upper body part to the lower part, increased relation of the arms span to the height with the absence of scoliosis USLS < 85 | 28 |
| Scoliosis, kyphosis | 26 |
| Limited strengthening of an elbow (<170°) | 3 |
| Dysmorphic facial features (≥3 z 5) | 14 |
| Stretch marks | 16 |
| Myopia > 3 Dioptres | 17 |
| Mitral valve prolapse | 20 |
The significance of the differences between a group with Marfan syndrome and a group of healthy people in the scope of the quality of life conditioned by the health status.
| Quality of Life Conditioned by the Health Status | Marfan Syndrome | Healthy People | Significance of Differences | 95% CI | ||||
|---|---|---|---|---|---|---|---|---|
| M | SD | M | SD | t |
| LL | UL | |
| PF | 74.85 | 16.93 | 93.03 | 9.60 | −5.37 | 0.000 | −24.95 | −11.41 |
| RP | 56.82 | 37.64 | 83.33 | 27.72 | −3.26 | 0.002 | −42.77 | −10.26 |
| BP | 54.88 | 21.33 | 57.58 | 23.15 | −0.49 | 0.625 | −13.64 | 8.25 |
| GH | 29.85 | 19.54 | 53.18 | 17.85 | −5.06 | 0.000 | −32.54 | −14.13 |
| VT | 53.03 | 14.57 | 60.91 | 18.81 | −1.90 | 0.062 | −16.15 | 0.40 |
| SE | 71.21 | 18.88 | 62.88 | 25.09 | 1.52 | 0.132 | −2.59 | 19.25 |
| RE | 69.70 | 40.28 | 81.82 | 34.45 | −1.31 | 0.194 | −30.55 | 6.31 |
| MH | 64.97 | 14.66 | 69.21 | 14.19 | −1.19 | 0.237 | −11.34 | 2.85 |
| PCS | 49.15 | 8.41 | 58.76 | 6.49 | −5.20 | 0.000 | −13.30 | −5.91 |
| MCS | 48.64 | 7.06 | 50.97 | 8.40 | −1.22 | 0.226 | −6.15 | 1.48 |
| GS SF-36 | 97.79 | 14.06 | 109.73 | 13.86 | −3.47 | 0.000 | −18.81 | −5.07 |
Note: PF—Physical Functioning, RP—Role-physical, BP—Bodily Pain, GH—General Health, VT—Vitality, SF—Social Functioning, RE—Role-emotional, MH—Mental Health, PCS—Physical Component Summary, MCS—Mental Component Summary, GS—General Scale.
Comparison of mean results obtained in different areas of the quality of life in both studied groups with regards to gender.
| Quality of Life Conditioned by the Health Status | Marfan Syndrome | Healthy People | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| K | M | Significance of Differences | K | M | Significance of Differences | |||||||
| M | SD | M | SD | t |
| M | SD | M | SD | t |
| |
| PF | 66.50 | 13.19 | 87.69 | 13.94 | −4.41 | 0.000 | 91.43 | 9.24 | 95.83 | 9.96 | −1.28 | 0.210 |
| RP | 57.50 | 34.51 | 55.77 | 43.49 | 0.13 | 0.900 | 80.95 | 27.28 | 87.50 | 29.19 | −0.65 | 0.523 |
| BP | 55.56 | 23.08 | 53.85 | 19.16 | 0.22 | 0.826 | 54.50 | 20.76 | 62.96 | 26.94 | −1.01 | 0.320 |
| GH | 24.25 | 17.34 | 38.46 | 20.25 | −2.15 | 0.039 | 52.62 | 16.25 | 54.17 | 21.09 | −0.24 | 0.815 |
| VT | 46.50 | 10.27 | 63.08 | 14.80 | −3.81 | 0.001 | 59.76 | 18.20 | 59.76 | 18.20 | −0.46 | 0.650 |
| SE | 69.38 | 20.06 | 65.00 | 43.90 | −0.69 | 0.497 | 59.76 | 18.20 | 69.79 | 18.04 | −1.21 | 0.237 |
| RE | 65.00 | 43.90 | 76.92 | 34.39 | −0.83 | 0.415 | 77.78 | 37.02 | 88.89 | 29.59 | −0.89 | 0.381 |
| MH | 60.20 | 15.65 | 72.31 | 9.45 | −2.50 | 0.018 | 68.00 | 15.28 | 71.33 | 12.40 | −0.64 | 0.525 |
| PCS | 46.45 | 6.99 | 53.31 | 8.97 | −2.46 | 0.020 | 57.95 | 5.67 | 60.17 | 7.78 | −0.94 | 0.354 |
| MCS | 45.85 | 6.29 | 52.92 | 6.13 | −3.19 | 0.003 | 50.00 | 9.31 | 52.67 | 6.54 | −0.87 | 0.389 |
| GS SF-36 | 92.30 | 11.20 | 106.23 | 14.19 | −3.14 | 0.004 | 107.95 | 14.40 | 112.83 | 12.87 | −0.97 | 0.339 |
Note: PF—Physical Functioning, RP—Role-physical, BP—Bodily Pain, GH—General Health, VT—Vitality, SF—Social Functioning, RE—Role-emotional, MH—Mental Health, PCS—Physical Component Summary, MCS—Mental Component Summary, GS—General Scale.
Correlations of a subjective assessment of the effects of health problems on life in the evaluation of people with Marfan syndrome and the quality of life.
| SF-36 | PF | RP | BP | GH | VT | SE | RE | MH | PCS | MCS | GS SF-36 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Orthopedic problems | −0.72 ** | −0.10 | 0.17 | −0.58 * | −0.71 * | −0.54 * | −0.51 | −0.52 * | −0.61 * | −0.76 ** | −0.73 * |
| Ophthalmic problems | −0.34 | 0.05 | 0.31 | −0.39 | −0.57 * | −0.19 | −0.20 | −0.15 | −0.21 | −0.46 | −0.36 |
| Cardiological problems | −0.37 | −0.61 * | 0.07 | −0.33 | −0.11 | −0.19 | −0.49 | −0.28 | −0.42 | −0.35 | −0.41 |
| Lower exercise tolerance | −0.52 * | −0.68 * | −0.23 | −0.34 | −0.39 | −0.54 * | −0.34 | −0.20 | −0.56 * | −0.49 | −0.56 * |
Explanation: * p < 0.05; ** p < 0.01;. Note: PF—Physical Functioning, RP—Role-physical, BP—Bodily Pain, GH—General Health, VT—Vitality, SF—Social Functioning, RE—Role-emotional, MH—Mental Health, PCS—Physical Component Summary, MCS—Mental Component Summary, GS—General Scale.
Correlation of the obtained Ghent points and a quality of life.
| SF-36 | PF | RP | BP | GH | VT | SE | RE | MH | PCS | MCS | GS SF-36 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Ghent points | −0.07 | 0.17 | 0.19 | −0.35 | −0.33 | 0.00 | −0.21 | −0.14 | −0.20 | −0.13 | −0.18 |
Note: PF—Physical Functioning, RP—Role-physical, BP—Bodily Pain, GH—General Health, VT—Vitality, SF—Social Functioning, RE—Role-emotional, MH—Mental Health, PCS—Physical Component Summary, MCS—Mental Component Summary, GS—General Scale.